Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction: Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness.
Ruiz de Garibay G, Herranz C, Llorente A, Boni J, Serra-Musach J, Mateo F, Aguilar H, Gómez-Baldó L, Petit A, Vidal A, Climent F, Hernández-Losa J, Cordero Á, González-Suárez E, Sánchez-Mut JV, Esteller M, Llatjós R, Varela M, López JI, García N, Extremera AI, Gumà A, Ortega R, Plà MJ, Fernández A, Pernas S, Falo C, Morilla I, Campos M, Gil M, Román A, Molina-Molina M, Ussetti P, Laporta R, Valenzuela C, Ancochea J, Xaubet A, Casanova Á, Pujana MA. Ruiz de Garibay G, et al. Among authors: pernas s. PLoS One. 2018 Nov 12;13(11):e0207586. doi: 10.1371/journal.pone.0207586. eCollection 2018. PLoS One. 2018. PMID: 30419005 Free PMC article.
SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022).
Garcia-Saenz JA, Blancas I, Echavarria I, Hinojo C, Margeli M, Moreno F, Pernas S, Ramon Y Cajal T, Ribelles N, Bellet M. Garcia-Saenz JA, et al. Among authors: pernas s. Clin Transl Oncol. 2023 Sep;25(9):2665-2678. doi: 10.1007/s12094-023-03203-8. Epub 2023 May 6. Clin Transl Oncol. 2023. PMID: 37148499 Free PMC article.
Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness.
Ruiz de Garibay G, Herranz C, Llorente A, Boni J, Serra-Musach J, Mateo F, Aguilar H, Gómez-Baldó L, Petit A, Vidal A, Climent F, Hernández-Losa J, Cordero Á, González-Suárez E, Sánchez-Mut JV, Esteller M, Llatjós R, Varela M, López JI, García N, Extremera AI, Gumà A, Ortega R, Plà MJ, Fernández A, Pernas S, Falo C, Morilla I, Campos M, Gil M, Román A, Molina-Molina M, Ussetti P, Laporta R, Valenzuela C, Ancochea J, Xaubet A, Casanova Á, Pujana MA. Ruiz de Garibay G, et al. Among authors: pernas s. PLoS One. 2015 Jul 13;10(7):e0132546. doi: 10.1371/journal.pone.0132546. eCollection 2015. PLoS One. 2015. PMID: 26167915 Free PMC article.
Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.
Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Català I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, García N, Perkins AS, Bonifaci N, Skowron M, Gómez-Baldó L, Hernández V, Martínez-Aranda A, Martínez-Iniesta M, Serrat X, Cerón J, Brunet J, Barretina MP, Gil M, Falo C, Fernández A, Morilla I, Pernas S, Plà MJ, Andreu X, Seguí MA, Ballester R, Castellà E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, Sánchez-Mut JV, Sánchez-Céspedes M, Cordero A, Gómez-Miragaya J, Palomero L, Gómez A, Gajewski TF, Cohen EEW, Jesiotr M, Bodnar L, Quintela-Fandino M, López-Bigas N, Valdés-Mas R, Puente XS, Viñals F, Casanovas O, Graupera M, Hernández-Losa J, Ramón Y Cajal S, García-Alonso L, Saez-Rodriguez J, Esteller M, Sierra A, Martín-Martín N, Matheu A, Carracedo A, González-Suárez E, Nanjundan M, Cortés J, Lázaro C, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA. Mateo F, et al. Among authors: pernas s. Oncogene. 2017 May 11;36(19):2737-2749. doi: 10.1038/onc.2016.427. Epub 2016 Dec 19. Oncogene. 2017. PMID: 27991928 Free PMC article.
Feasibility, accuracy and prognosis of sentinel lymph node biopsy before neoadjuvant therapy in breast cancer. A prospective study.
Garcia-Tejedor A, Falo C, Quetglas C, Soler T, Marqueta B, Ortega R, Gil-Gil M, Pernas S, Fernandez-Montolí E, Pla MJ, Guma A, Bajen M, Benitez A, Eraso A, Campos M, Petit A, Ponce J. Garcia-Tejedor A, et al. Among authors: pernas s. Int J Surg. 2017 Mar;39:141-147. doi: 10.1016/j.ijsu.2017.01.106. Epub 2017 Jan 30. Int J Surg. 2017. PMID: 28153783 Free article.
Radiofrequency Ablation Followed by Surgical Excision versus Lumpectomy for Early Stage Breast Cancer: A Randomized Phase II Clinical Trial.
García-Tejedor A, Guma A, Soler T, Valdivieso A, Petit A, Contreras N, Chappuis CG, Falo C, Pernas S, Amselem A, Plà MJ, Fernández-Montolí E, Burdío F, Ponce J. García-Tejedor A, et al. Among authors: pernas s. Radiology. 2018 Nov;289(2):317-324. doi: 10.1148/radiol.2018180235. Epub 2018 Aug 21. Radiology. 2018. PMID: 30129904 Clinical Trial.
Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
Pernas S, Petit A, Climent F, Paré L, Perez-Martin J, Ventura L, Bergamino M, Galván P, Falo C, Morilla I, Fernandez-Ortega A, Stradella A, Rey M, Garcia-Tejedor A, Gil-Gil M, Prat A. Pernas S, et al. Front Oncol. 2019 Sep 25;9:967. doi: 10.3389/fonc.2019.00967. eCollection 2019. Front Oncol. 2019. PMID: 31598491 Free PMC article.
Predictive factors for omitting lymphadenectomy in patients with node-positive breast cancer treated with neo-adjuvant systemic therapy.
Fernandez-Gonzalez S, Falo C, Pla MJ, Verdaguer P, Nuñez D, Guma A, Soler T, Vethencourt A, Vázquez S, Fernandez-Montoli ME, Campos M, Pernas S, Gil M, Ponce J, Garcia-Tejedor A. Fernandez-Gonzalez S, et al. Among authors: pernas s. Breast J. 2020 May;26(5):888-896. doi: 10.1111/tbj.13763. Epub 2020 Feb 13. Breast J. 2020. PMID: 32052521
Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.
Pernas S, Gil-Gil M, de Olza MO, Gumà A, Climent F, Petit A, Pla MJ, García-Tejedor A, López-Ojeda A, Falo C, Fernandez-Otega A, Mesia C, Pérez-Martin FJ, Urruticoechea A, Germà JR. Pernas S, et al. Breast Cancer Res Treat. 2012 Aug;134(3):1161-8. doi: 10.1007/s10549-012-2149-7. Epub 2012 Jul 8. Breast Cancer Res Treat. 2012. PMID: 22772380 Clinical Trial.
83 results